Medicinal Chemistry, Global Research & Development, Merck Healthcare KGaA, 64293 Darmstadt, Germany.
Discovery Chemistry, Genentech, South San Francisco, California 94080, United States.
J Med Chem. 2023 Jul 27;66(14):9297-9312. doi: 10.1021/acs.jmedchem.3c00550. Epub 2023 Jul 5.
Within druggable target space, new small-molecule modalities, particularly covalent inhibitors and targeted degraders, have expanded the repertoire of medicinal chemists. Molecules with such modes of action have a large potential not only as drugs but also as chemical probes. Criteria have previously been established to describe the potency, selectivity, and properties of small-molecule probes that are qualified to enable the interrogation and validation of drug targets. These definitions have been tailored to reversibly acting modulators but fall short in their applicability to other modalities. While initial guidelines have been proposed, we delineate here a full set of criteria for the characterization of covalent, irreversible inhibitors as well as heterobifunctional degraders ("proteolysis-targeting chimeras", or PROTACs) and molecular glue degraders. We propose modified potency and selectivity criteria compared to those for reversible inhibitors. We discuss their relevance and highlight examples of suitable probe and pathfinder compounds.
在可成药靶点范围内,新型小分子药物模式,特别是共价抑制剂和靶向降解剂,已经扩大了药物化学家的工具库。具有这些作用模式的分子不仅具有作为药物的巨大潜力,而且还具有作为化学探针的潜力。之前已经建立了标准来描述具有足够潜力的小分子探针的效力、选择性和性质,这些探针可用于探究和验证药物靶点。这些定义已经针对可逆作用调节剂进行了调整,但在适用于其他模式方面存在不足。虽然已经提出了初步的指导方针,但我们在这里详细描述了一套全面的标准,用于描述共价不可逆抑制剂以及双功能降解剂(“蛋白水解靶向嵌合体”或 PROTAC)和分子胶降解剂的特性。与可逆抑制剂相比,我们提出了修改后的效力和选择性标准。我们讨论了它们的相关性,并强调了合适的探针和先导化合物的例子。